secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-050164
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance
------------------------------------------------------------------------

- Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.
- Adjusted EBITDA $24.6M, up 39% from $17.7M; non-GAAP EPS $0.16 vs $0.12.
- Stent grafts +38%, On-X +25%, preservation +5%, BioGlue +2% YoY.
- Enrolled first patient in ARTIZEN IDE trial for Arcevo; refinanced credit to 2031 with $150M delayed draw.
- Raises FY 2025 revenue guidance to $439-$445M (prev $435-$443M) and EBITDA to $88-$91M (prev $86-$91M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000162828025050164/0001628280-25-050164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000162828025050164/aort-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-050164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer